Evidence map›Paper›PMID 25893735›Full record

ArticleMolecular and cellular biochemistry2015

Activation of GPR30 inhibits cardiac fibroblast proliferation.

Hao Wang, Zhuo Zhao, Marina Lin, Leanne Groban

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Role of estrogen receptors in health and disease.Frontiers in endocrinology · 2022
    Review
  16. Review
  17. Matters of the heart: Cellular sex differences.Journal of molecular and cellular cardiology · 2021
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Hao WangDepartment of Anesthesiology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1009, USA.
Zhuo Zhao
Marina Lin
Leanne Groban
Wake Forest University · US

Funding

Interplay Between Estrogen, GPR30 and Chymase/RAS in Diastolic FunctionR01AG033727 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI GROBAN, LEANNE · 2009 to 2017
$2.8M
The conditional GPR30 knockout mouse: a model of female-specific cardiac agingR03AG042758 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI GROBAN, LEANNE · 2012 to 2013
$144k
NIA NIH HHS AG-033727NIA NIH HHS AG-042758NIA NIH HHS R01 AG033727NIA NIH HHS R03 AG042758
6 · The paper itself

Abstract

The incidence of left ventricular diastolic dysfunction significantly increases in postmenopausal women suggesting the association between estrogen loss and diastolic dysfunction. The in vivo activation of G protein-coupled estrogen receptor (GPR30) attenuates the adverse effects of estrogen loss on cardiac fibrosis and diastolic dysfunction in mRen2.Lewis rats. This study was designed to address the effects of GPR30 on cardiac fibroblast proliferation in rats. The expression of GPR30 in cardiac fibroblasts isolated from adult Sprague-Dawley rats was confirmed by RT-PCR, Western blot analysis, and immunofluorescence staining. Results from BrdU incorporation assays, cell counting, carboxyfluorescein diacetate succinimidyl ester labeling in conjunction with flow cytometry, and Ki-67 staining showed that treatment with G1, a specific agonist of GPR30, inhibited cardiac fibroblast proliferation in a dose-dependent manner, which was associated with decreases in CDK1 and cyclin B1 protein expressions. In the GPR30-KO cells, BrdU incorporation, and CDK1 and cyclin B1 expressions significantly increased when compared to GPR30-intact cells. G1 had no effect on BrdU incorporation, CDK1 and cyclin B1 mRNA levels in GPR30-KO cells. In vivo studies showed increases in CDK1 and cyclin B1 mRNA levels, Ki-67-positive cells, and the immunohistochemistry staining of vimentin, a fibroblast marker, in the left ventricles from ovariectomized mRen2.Lewis rats versus hearts from ovary-intact littermates; 2 weeks of G1 treatment attenuated these adverse effects of estrogen loss. This study demonstrates that GPR30 is expressed in rat cardiac fibroblasts, and activation of GPR30 limits proliferation of these cells likely via suppression of the cell cycle proteins, cyclin B1, and CDK1.

Indexed as

AnimalsBiomarkersCDC2 Protein KinaseCell Cycle ProteinsCell ProliferationCyclin B1Cyclin-Dependent KinasesEstrogensFibroblastsHeart VentriclesKi-67 AntigenMaleOvariectomyRatsRats, Sprague-DawleyReceptors, G-Protein-CoupledBiomarkersCcnb1 protein, ratCDC2 Protein KinaseCdk1 protein, ratCell Cycle ProteinsCyclin B1Cyclin-Dependent KinasesEstrogensGper1 protein, ratKi-67 AntigenReceptors, G-Protein-CoupledRNA, MessengerVimentin

Identifiers

PMID25893735
PMCPMC4449333
OpenAlexW1980166578

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.